Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'- didehydro-β-L-5-fluorocytidine in the duck hepatitis B virus infection model

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 1, 2000, Pages 111-122

  Le Guerhier, Franck ^a   Pichoud, Christian ^a   Guerret, Sylviane ^b   Chevallier, Michèle ^b   Jamard, Catherine ^a   Hantz, Olivier ^a   Li, Xiu Yan ^c   Chen, Shu Hui ^c   King, Ivan ^c   Trépo, Christian ^a   Cheng, Yung Chi ^d   Zoulim, Fabien ^a  

^a INSERM   (France)

^b Department of Pathology   (France)

^c Vion Pharmaceuticals Incorporated   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ELVUCITABINE; LAMIVUDINE; VIRUS DNA; ZALCITABINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DUCK; HEPATITIS B; HEPATITIS B VIRUS; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0033988351     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.1.111-122.2000     Document Type: Article

References (44)

1. Aguesse-Germon, S., S.-H. Liu, M. Chevallier, C. Pichoud, C. Jamard, C. Borel, C. K. Chu, C. Trépo, Y.-C. Cheng, and F. Zoulim. 1998. Inhibitory effect of 2′-fluoro-5-methyl-β-L-arabinofuranosyl-uracyl on duck hepatitis B virus replication. Antimicrob. Agents Chemother. 42:369-376.
2. Chang, C.-N., S.-L. Doong, J. H. Zhou, J. W. Beach, L. S. Jeong, C. K. Chu, C.-H. Tsai, and Y.-C. Cheng. 1992. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±) 2′,3′ dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. 267:13938-13942.
3. Chassot, S., V. Lambert, A. Kay, C. Godinot, B. Roux, C. Trépo, and L. Cova. 1993. Fine mapping of neutralization epitopes on duck hepatitis B virus (DHBV) pre-S protein using monoclonal antibodies and overlapping peptides. Virology 192:217-223.
4. Dannaoui, E., C. Trépo, and F. Zoulim. 1997. Inhibitory effect of penciclovir-triphosphate on duck hepatitis B virus reverse transcription. Antivir. Chem. Chemother. 8:38-46.
5. Diaz-Guerra, M., C. Rivas, and M. Esteban. 1997. Activation of the IFN-inducible enzyme RNase L causes apoptosis of animal cells. Virology 236: 354-363.
6. Doong, S.-L., C.-H. Tsai, R. F. Schinazi, D. C. Liotta, and Y.-C. Cheng. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA 88:8495-8499.
7. Dutschman, G. E., E. G. Bridges, S.-H. Liu, E. Gullen, X. Guo, M. Kukhanova, and Y.-C. Cheng. 1998. Metabolism of 2′,3′-dideoxy-2′,3′-didehydroβ-I.(-)-5- fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus β-D(+) nucleoside analogs in vitro. Antimicrob. Agents Chemother. 42:1799-1804.
8. Fourel, I., J. M. Cullen, J. Saputelli, C. E. Aldrich, P. Schaffer, D. R. Averett, J. Pugh, and W. S. Mason. 1994. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J. Virol. 68:8321-8330.
9. Fourel, I., J. Saputelli, P. Schaffer, and W. S. Mason. 1994. The carbocyclic analog of 2′-deoxyguanosine induces a prolonged inhibition of duck hepatitis B virus DNA synthesis in primary hepatocyte cultures and in the liver. J. Virol. 68:1059-1065.
10. Genovesi, E. V., L. Lamb, I. Medina, D. Taylor, M. Seifer, S. Innaimo, R. J. Colonno, D. N. Standring, and J. M. Clark. 1998. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob. Agents Chemother. 42:3209-3217.
11. Hantz, O., C. Borel, C. Trabaud, F. Zoulim, J. Dessolin, M. Camplo, P. Vlieghe, M. Bouygues, C. Trépo, and J. L. Kraus. 1997. Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles. Antimicrob. Agents Chemother. 41:2579-2581.
12. Hoofnagle, J. H., and A. M. Di Bisceglie. 1997. The treatment of chronic viral hepatitis. N. Engl. J. Med. 336:347-356.
13. Jilbert, A. R., T. T. Wu, J. M. England, P. De La M. Hall, N. Z. Carp, A. P. O'Connell, and W. S. Mason. 1992. Rapid resolution of duck hepatitis B virus infections occurs after massive hepatocellular involvement. J. Virol. 66:1377-1388.
14. Kock, J., and H. G. Schlicht. 1993. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J. Virol. 67:4867-4874.
15. Kukhanova, M., X. Li, S.-H. Chen, I. King, T. Doyle, W. Prusoff, and Y.-C. Cheng. 1998. Interaction of β-L-2′,3′-dideoxy-2′,3′-didehydro-5-fluoro-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: implications for human immunodeficiency virus drug design. Mol. Pharmacol. 53:801-807.
16. Lai, C. L., R. W. Chine, N. W. Y. Leung, T. T. Chang, R. Guan, D. I. Tai, K. Y. Ng, P. C. Wu, J. C. Dent, J. Barber, S. L. Stephenson, and F. Gray. 1998. A one year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339: 61-68.
17. Lambert, V., S. Chassot, A. Kay, C. Trépo, and L. Cova. 1991. In vivo neutralization of duck hepatitis B virus by antibodies specific to the N-terminal portion of pre-S protein. Virology 185:446-450.
18. Lee, W. 1995. Drug-induced hepatotoxicity. N. Eng. J. Med. 333:1118-1127.
19. Lee, W. M. 1997. Hepatitis B virus infection. N. Eng. J. Med. 337:1733-1745.
20. Lin, E., C. Luscombe, D. Colledge, Y. Y. Wang, and S. Locarnini. 1998. Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo. Antimicrob. Agents Chemother. 42:2132-2137.
21. Lin, T.-S., M.-Z. Luo, M.-C. Liu, S.-B. Pai, G.-E. Dutschman, and Y.-C. Cheng. 1994. Antiviral activity of 2′,3′-dideoxy-β-L-5-Fluorocytidine (β-L-F-ddC) and 2′,3′-dideoxy-β-L-cytidine (β-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem. Pharmacol. 47:171-174.
22. Lin, T.-S., M.-Z. Luo, M.-C. Liu, S. B. Pai, G. E. Dutschman, and Y.-C. Cheng. 1994. Synthesis and biological evaluation of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). J. Med. Chem. 37:798-803.
23. Lin, T.-S., M.-Z. Luo, M.-C. Liu, Y.-L. Zhu, E. Gullen, G. E. Dutschmann, and Y.-C. Cheng. 1996. Design and synthesis of 2′,3′-dideoxy-2′,3′-didehydro-β-L-cytidine (β-L-d4C) and 2′,3′-dideoxy-2′,3′-didehydro-β-L-5-fluorocytidine (β-L-Fd4C), two exceptionally potent inhibitors of human hepatitis B virus (HBV) and potent human immunodeficiency virus (HIV) in vitro. J. Med. Chem. 39:1757-1759.
24. Mason, W. S., J. Cullen, G. Moraleda, J. Saputelli, C. E. Aldrich, D. S. Miller, B. Tennant, L. Frick, D. Averett, L. D. Condreay, and A. R. Jilbert. 1998. Lamivudine therapy of WHV-infected woodchucks. Virology 245:18-32
25. Mason, W. S., and J. M. Taylor. 1989. Experimental systems for the study of hepadnavirus and hepatitis delta virus infections. Hepatology 9:635-645.
26. Moraleda, G., J. Saputelli, C. E. Aldrich, D. Averett, L. Condreay, and W. S. Mason. 1997. Lack of effect of antiviral therapy in nondividing hepatocyle cultures on the closed circular DNA of woodchuck hepatitis virus. J. Virol. 71:9392-9399.
27. Nevens, F., J. Main, P. Honkoop, D. L. Tyrrell, J. Barber, M. T. Sullivan, J. Fevery, R. De Man, and H. C. Thomas. 1997. Lamivudine therapy for chronic hepatitis B: a six month randomized dose-ranging study. Gastroenterology 113:1258-1263.
28. Nowak, M., S. Bonhoeffer, A. Hill, R. Boehme, H. Thomas, and H. McDade. 1996. Viral dynamics in hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 93:4398-4402.
29. Pichoud, C., B. Seignères, Z. Wang, C. Trepo, and F. Zoulim. 1999. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 29: 230-237.
30. Seifer, M., R. K. Hamatake, R. J. Colonno, and D. N. Standring. 1998. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob. Agents Chemother. 42:3200-3208.
31. Severini, A., X.-Y. Liu, J. Wilson, and D. Tyrell. 1995. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy-3′-thyacytidine. Antimicrob. Agents Chemother. 39:1430-1435.
32. Shaw, T., P. Amor, G. Civitico, M. Boyd, and S. Locarnini. 1994. In vitro antiviral activity of penciclovir, a novel purine nucleoside, against duck hepatitis B virus. Antimicrob. Agents Chemother. 38:719-723.
33. Staschke, K., and J. Colacino. 1994. Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5′-triphosphate of fialuridine. J. Virol. 68:8265-8269.
34. Summers, J., P. M. Smith, and A. L. Horwich. 1990. Hepadnaviral envelope proteins regulate covalently closed circular DNA amplification. J. Virol. 64:2819-2824.
35. Trigueiro de Araujo, M. S., S. Guerret, F. Gérard, P. Chossegros, M. Chevallier, and J. A. Grimaud. 1997. Quantitative studies on liver fibrosis and alpha-smooth muscle actin expression in heroin abusers. Cell. Mol. Biol. 43:589-596.
36. Tuttleman, J., C. Pourcel, and J. Summers. 1986. Formation of the pool of covalently closed circular viral DNA in hepadnavirus infected cells. Cell 47:451-460.
37. Tuttleman, J. S., J. C. Pugh, and J. W. Summers. 1986. In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J. Virol. 58:17-25.
38. Wang, G. H., and C. Seeger. 1993. A novel mechanism for reverse transcription in hepatitis B viruses. J. Virol. 67:6507-6512.
39. Wang, G. H., and C. Seeger. 1992. The reverse transcriptase of hepatitis B virus acts a protein primer for viral DNA synthesis. Cell 71:663-670.
40. Wu, T.-T., L. Coates, C. E. Aldrich, J. Summers, and W. S. Mason. 1990. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 175:255-261.
41. Zhu, Y.-L., G. E. Dutschman, S.-H. Liu, E. G. Bridges, and Y.-C. Cheng. 1998. Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′-didehydro-β-L(-)-5- fluorocytidine. Antimicrob. Agents Chemother. 42:1805-1810.
42. Zoulim, F., E. Dannaoui, C. Borel, O. Hantz, T.-S. Lin, S.-H. Liu, C. Trépo, and Y.-C. Cheng. 1996. 2′,3′-dideoxy-β-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo. Antimicrob. Agents Chemother. 40: 448-453.
43. Zoulim, F., and C. Seeger. 1994. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J. Virol. 68:6-13.
44. Zoulim, F., and C. Trépo. 1998. Drug therapy for chronic hepatitis B: antiviral efficacy and influence of hepatitis B virus polymerase mutations on the outcome of therapy. J. Hepatol. 29:151-168.